Vasomotor Symptoms Due To Menopause — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for vasomotor symptoms due to menopause. 4 active patents protecting 1 drugs from 1+ originators. First major cliff: 2031. Daily refresh.

1
Approved drugs
4
Active US patents
57/100
Avg vulnerability
—
Annual revenue covered

Originators in Vasomotor Symptoms Due To Menopause

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Astellas Pharma 4 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating vasomotor symptoms due to menopause. Each bar = one year. Y-axis scaled to peak year (3 patents).

1
31
3
34

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Veozah
FEZOLINETANT
 Astellas Pharma 4 57 — 2031-04-04

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
9987274 Veozah method of use 70 2034-03-28
9422299 Veozah method of use 70 2034-03-28
10836768 Veozah method of use 70 2034-03-28
8871761 Veozah composition of matter 18 2031-04-04

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8871761 Veozah composition of matter 18 2031-04-04
9987274 Veozah method of use 70 2034-03-28
9422299 Veozah method of use 70 2034-03-28
10836768 Veozah method of use 70 2034-03-28

Related